Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

University of Florida, Gainesville, and a lead investigator in this Phase IIb study.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treat
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s ... , Chairman & CEO, and Sean Whelan , CFO, ... Mr. Hagerman and Mr. Whelan are scheduled to participate in ... on Wednesday, September 9, 2015 at 1:45 PM ... scheduled to participate in the Robert W. Baird 2015 Healthcare ...
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... 13 Solta Medical, Inc. (Nasdaq: SLTM ), a global ... the Provectus Award presented by MDB Capital Group at the first annual ... companies with disruptive and market changing intellectual property (IP). , ... "We are honored to have our ...
... NEW YORK , May 12 Delcath Systems, ... medical device company focused on oncology, today announced that it will ... . The ceremony at the NASDAQ MarketSite at Times Square in ... 9:22 a.m. Eastern time via the NASDAQ webcam. The ...
Cached Medicine Technology:Solta Medical Receives Provectus Innovation Award at MDB Capital Group's Bright Lights Intellectual Property Conference 2Solta Medical Receives Provectus Innovation Award at MDB Capital Group's Bright Lights Intellectual Property Conference 3Delcath's Eamonn Hobbs to Ring NASDAQ Opening Bell 2
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
(Date:8/31/2015)... Illinois (PRWEB) , ... August 31, 2015 , ... ... their AdvantaClean franchise business with a ribbon-cutting ceremony on Aug. 26, generously hosted ... calls and booking inspection appointments via AdvantaClean’s National Call Center and website since ...
(Date:8/31/2015)... ... 31, 2015 , ... Physicians’ Education Resource®, LLC (PER®) ... Innovative Cancer Therapy for Tomorrow® meeting, is seeking abstract submissions for its ... City. The annual legacy meeting uses a variety of formats to educate all ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... peers may be at a greater risk for injury, potentially because they are ... University of Pittsburgh Graduate School of Public Health analysis discovered. , The ...
(Date:8/31/2015)... ... August 31, 2015 , ... On Saturday, May 30th, ... at the Adams County Fairgrounds in Mendon, IL. The purpose behind this concert was ... Mendon and neighboring town, Quincy. Best Drug Rehabilitation’s sponsorship of “Music with a Mission” ...
Breaking Medicine News(10 mins):Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3
... really mysterious, however these have inspired a computational technique ... affected by the// personality disorder schizophrenia. Researchers feel the ... that can help diagnose the condition. ,Exactly ... schizophrenia is yet to be pinned down. Raymond Deicken ...
... abuse can be moderately improved by various psychotherapy treatments ... the best clinicians// can hope for at this time, ... behavioral therapy (CBT) is most effective, but other counseling ... social problems associated with their marijuana use. ...
... and Clinical Excellence (NICE) has brought out guidance to ... to help adult patients suffering acute plaque psoriasis. Despite ... benefits for many patients in Europe due to the ... for many thousands of patients across United Kingdom who ...
... research done by Eyal Raz, Sandip Datta and Joshua ... Medicine it was found that gamma radiation// killed bacteria ... against the bacterial disease. ,The U.S. National ... researches in their finding and said that these bacterial ...
... who completed a management course here and agreed to be part ... effects of the trial and is looking// forward to returning to ... trial for US testing firm Parexel in March, but is now ... He is reported to be taking antidepressants and medication to stop ...
... which a specific cell protein trigger the spread of cancer ... by researchers in the Cell Signalling Unit, University of Edinburgh ... which limit the protein's ability to turn a normal cell ... the activity of a key cancer preventing protein called p53. ...
Cached Medicine News:Health News:Diagnosing Schizophrenia 2Health News:Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat 2Health News:Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat 3Health News:NICE supports application of advanced biological therapies as treatment option for acute psoriasis 2Health News:NICE supports application of advanced biological therapies as treatment option for acute psoriasis 3Health News:NICE supports application of advanced biological therapies as treatment option for acute psoriasis 4
Ideal for abdominal procedures...
For lipoplasty of trochanteric region, abdomen, thighs, hips/flanks, buttocks, knees, calves and ankles...
CDIs original garments with our exclusive Wonderfabric™....
Short Girdle, Mid-thigh, Front Closure...
Medicine Products: